Those without mutation in either marker had only a slightly better outcome (median OS 17 months), while those with an IDH1/2 mutation alone, the signature characteristic of Grade II-III astrocytomas and Grade IV secondary GBMs, had the best outcome among the Grade IV tumors (median OS 42 months). The gene discussed is IDH1; the disease is astrocytoma (excluding glioblastoma).